Clinical Edge Journal Scan

Invasive breast cancer: Vertebral fractures common in patients receiving endocrine therapy


 

Key clinical point: The possibility of cancer-related or pathologic vertebral fracture should be considered in women with invasive breast cancer who received endocrine therapy, particularly those with, advanced stage cancer history where every 1 in 3 incident vetrtebral fractures was a pathologic fracture.

.Major finding: Overall, 21.2% of vertebral fractures were pathologic with the chances of vertebral fractures being pathologic higher in patients with stage 3-4 vs initial stage 1 and 2 breast cancer (41.2% vs 17.2%; P < .05).

Study details: Findings are from a cohort study including 5010 women with newly-diagnosed invasive breast cancer who received endocrine therapy and were followed up from invasive breast cancer diagnosis to 10 years or until September 30, 2015, for incident bone fracture.

Disclosures: This study was funded by the National Cancer Institute, National Institutes of Health, and the Research Program on Genes, Environment and Health of Kaiser Permanente Northern California. The authors declared no conflicts of interest.

Source: Lo JC et al. JAMA Netw Open. 2021 Nov 17. doi: 10.1001/jamanetworkopen.2021.33861.

Recommended Reading

Cardiovascular effects of breast cancer treatment vary based on weight, menopausal status
MDedge Hematology and Oncology
Postmenopausal women with early breast cancer can go chemo-free
MDedge Hematology and Oncology
Chemoendocrine therapy beneficial in premenopausal women with node+ breast cancer and low recurrence score
MDedge Hematology and Oncology
Long-term ovarian suppression with GnRHa safe in premenopausal early breast cancer
MDedge Hematology and Oncology
HER2-negative breast cancer: Adding dalpiciclib to fulvestrant prolongs PFS in phase 3
MDedge Hematology and Oncology
HER2-negative advanced breast cancer: LY2780301 + paclitaxel combo shows promise in phase 1b/2
MDedge Hematology and Oncology
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide improves survival in HR+/HER2- BC
MDedge Hematology and Oncology
Impact of COVID-19 pandemic on breast cancer stage at diagnosis and management strategies
MDedge Hematology and Oncology
Node-positive breast cancer: Internal mammary node irradiation may benefit patients with mediocentrally located tumors
MDedge Hematology and Oncology
Metastatic breast cancer: Small subset of patients may benefit from rupacrib
MDedge Hematology and Oncology